- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Sustainable Track Record
U.S. Pharmaceuticals & Biotech Sustainable Track Record
Results
17
Companies which have reinvested earnings to sustain 10% yearly growth over 5 years.
17 companies
Niagen Bioscience
Market Cap: US$550.2m
Operates as a bioscience company engages in developing healthy aging products.
NAGE
US$6.93
7D
-2.4%
1Y
-4.7%
CytomX Therapeutics
Market Cap: US$657.4m
Operates as an oncology-focused biopharmaceutical company that focuses on developing novel conditionally activated biologics localized to the tumor microenvironment.
CTMX
US$3.55
7D
-15.3%
1Y
311.3%
Merck
Market Cap: US$230.6b
Operates as a healthcare company worldwide.
MRK
US$92.86
7D
7.0%
1Y
-3.8%
Incyte
Market Cap: US$20.4b
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan.
INCY
US$104.17
7D
-1.7%
1Y
35.3%
Harmony Biosciences Holdings
Market Cap: US$2.0b
A commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States.
HRMY
US$33.99
7D
6.8%
1Y
2.8%
Medpace Holdings
Market Cap: US$16.6b
Provides clinical research-based drug and medical device development services in North America, Europe, and Asia.
MEDP
US$585.76
7D
-2.4%
1Y
89.6%
Exelixis
Market Cap: US$11.2b
An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.
EXEL
US$42.42
7D
2.4%
1Y
22.9%
ACADIA Pharmaceuticals
Market Cap: US$4.1b
A biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States.
ACAD
US$24.01
7D
8.2%
1Y
41.0%
ADMA Biologics
Market Cap: US$3.7b
A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.
ADMA
US$15.42
7D
4.8%
1Y
-21.1%
BioStem Technologies
Market Cap: US$66.6m
A life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services.
BSEM
US$3.35
7D
-27.2%
1Y
-75.4%
Puma Biotechnology
Market Cap: US$246.4m
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally.
PBYI
US$4.96
7D
4.9%
1Y
81.0%
Catalyst Pharmaceuticals
Market Cap: US$2.8b
A commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States.
CPRX
US$22.56
7D
4.6%
1Y
8.4%
Rigel Pharmaceuticals
Market Cap: US$761.3m
A biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer.
RIGL
US$42.51
7D
23.0%
1Y
86.9%
Halozyme Therapeutics
Market Cap: US$8.2b
A biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally.
HALO
US$70.56
7D
3.7%
1Y
65.8%
Oramed Pharmaceuticals
Market Cap: US$92.8m
Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
ORMP
US$2.34
7D
2.6%
1Y
7.8%
Eli Lilly
Market Cap: US$918.0b
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally.
LLY
US$1,021.70
7D
5.7%
1Y
40.5%
Earth Science Tech
Market Cap: US$41.6m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.14
7D
-12.5%
1Y
16.8%